OPKO Health, Inc. (NASDAQ:OPK) Given Average Rating of “Hold” by Analysts

OPKO Health, Inc. (NASDAQ:OPK) has earned a consensus rating of “Hold” from the six brokerages that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, four have issued a hold rating and one has issued a strong buy rating on the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $1.55.

Several equities analysts recently issued reports on OPK shares. Wall Street Zen upgraded shares of OPKO Health from a “sell” rating to a “hold” rating in a report on Saturday, June 6th. Weiss Ratings upgraded shares of OPKO Health from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, May 18th. Finally, Barrington Research lowered shares of OPKO Health from an “outperform” rating to a “market perform” rating in a report on Wednesday, April 29th.

Hedge Funds Weigh In On OPKO Health

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Goldman Sachs Group Inc. raised its holdings in shares of OPKO Health by 150.9% during the fourth quarter. Goldman Sachs Group Inc. now owns 5,986,913 shares of the biotechnology company’s stock valued at $7,544,000 after purchasing an additional 3,600,378 shares during the period. Millennium Management LLC raised its holdings in shares of OPKO Health by 39.2% during the first quarter. Millennium Management LLC now owns 6,386,911 shares of the biotechnology company’s stock valued at $10,602,000 after purchasing an additional 1,798,385 shares during the period. AQR Capital Management LLC raised its holdings in shares of OPKO Health by 466.7% during the first quarter. AQR Capital Management LLC now owns 1,608,906 shares of the biotechnology company’s stock valued at $2,671,000 after purchasing an additional 1,324,988 shares during the period. OP Asset Management Ltd acquired a new position in shares of OPKO Health during the first quarter valued at about $1,257,000. Finally, HRT Financial LP acquired a new position in shares of OPKO Health during the fourth quarter valued at about $851,000. Institutional investors and hedge funds own 64.63% of the company’s stock.

OPKO Health Stock Performance

Shares of OPKO Health stock opened at $1.49 on Thursday. The stock has a market cap of $1.13 billion, a price-to-earnings ratio of -5.52 and a beta of 1.50. The company has a quick ratio of 3.17, a current ratio of 3.61 and a debt-to-equity ratio of 0.28. OPKO Health has a twelve month low of $0.98 and a twelve month high of $1.60. The company’s fifty day moving average is $1.28 and its 200 day moving average is $1.26.

OPKO Health (NASDAQ:OPK) last released its earnings results on Tuesday, April 28th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.07). The business had revenue of $124.20 million for the quarter, compared to analyst estimates of $130.51 million. OPKO Health had a negative net margin of 36.63% and a negative return on equity of 16.78%. OPKO Health’s revenue for the quarter was down 17.1% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.10) earnings per share. Sell-side analysts forecast that OPKO Health will post -0.29 EPS for the current year.

OPKO Health Company Profile

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.